ArticleCancer biology & therapy2015

A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.

Lucely Cetina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.